New BC PharmaCare Coverage Discriminatory to Adults with ADHD

On April 18th BC PharmaCare announced that it was expanding its existing coverage of medications for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in the paediatric population. Three long acting ADHD medications (Adderall XR, Vyvanse and Strattera) will be added under the Special Authority (SA) program. The SA program covers medications for patients under…

Are we Prescribing too Many Antipsychotic Medications for Children with ADHD?

A recent study by the Institute for Clinical Evaluative Sciences found almost 12 per cent of children and youth with attention deficit hyperactivity disorder, or ADHD, were prescribed antipsychotics like Risperdal, Zyprexa and Seroquel. Since the study found that 5% of Ontario children have ADHD, this means that .06% of children may be receiving antipsychotic…

Follow–up from Health Canada regarding Generic Forms of Concerta

This past week, a follow-up letter was received from Marion Law, the Director General of Health Canada’s Therapeutic Products Directorate (TPD) addressing discussions during the Oct 31 meeting with Janssen, CADDAC  and ADHD medical experts. The letter noted that: During the meeting with Health Canada, concerns were expressed by patient and physician organizations about the…

Recent Meeting with Health Canada Regarding Generic Concerta

On October the 31st CADDAC and CADDRA, as well as other stake holders, met with Health Canada to present our activities over the past six years and express our continued concerns in regards to the bioequivalency, or more accurately the lack of therapeutic equivalence, of the generic forms of the brand name ADHD medication Concerta. …